Over the past decade, severaldrugs targeting the preproglucagon gene signaling systems, particularly GLP-1,have been developed for treating T2D and obesity, with increasing interest in Gcgagonists as part of multi-receptor therapies for cardiometabolic diseases [20].However, the therapeutic potential of targeting the Gcg receptor has beenunderexplored, largely due to concerns regarding hyperglycemia [31]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.